Streetbeat News

Regulatory

JNJ

Johnson & Johnson has submitted a supplemental New Drug Application (NDA) to the U.S. FDA to expand the pediatric indication for its HIV-1 therapy, PREZCOBIX.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 8:34 pm

GME

MS

Morgan Stanley's E-Trade is reportedly considering a ban on Keith Gill's trading account due to potential stock manipulation after he disclosed a significant position in GameStop. Professional trader Dennis Dick criticized the potential ban, arguing that buying call options is not illegal. Gill's recent social media activity and disclosure of his GameStop position led to a significant increase in GameStop's stock price.

Portfolio Pulse from Aaron Bry

June 04, 2024 | 8:32 pm

CLLS

Cellectis announced that the European Commission has granted Orphan Drug Designation to its product candidate UCART22 for the treatment of Acute Lymphoblastic Leukemia. UCART22 is an allogeneic CAR T-cell product targeting CD22, currently in a Phase 1/2 study.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 8:31 pm

MSAI

MultiSensor AI Holdings, Inc. (NASDAQ:MSAI) has achieved compliance with Nasdaq's continued listing criteria, ensuring its removal from the noncompliant list. This development was confirmed through a written notification from Nasdaq and detailed in the company's Current Report on Form 8-K.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 8:29 pm

HSCS

HeartSciences has regained compliance with Nasdaq listing requirements, ensuring its continued presence on the exchange.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 8:19 pm

GTI

Graphjet Technology (NASDAQ:GTI) received a delinquency notification from Nasdaq for failing to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. The company is working to resolve the issue, and the notice has no immediate effect on its Nasdaq listing.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 8:19 pm

RPTX

Repare Therapeutics has received FDA Fast Track designation for its drug Lunresertib in combination with Camonsertib for the treatment of platinum-resistant ovarian cancer.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 8:09 pm

MGRX

Mangoceuticals, Inc. (NASDAQ:MGRX) has received a Notice of Allowance for a Japanese patent application for its preventive care technology. This follows the company's acquisition of a global patent portfolio from Intramont Technologies, expanding its protection for formulations combating infections.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 8:00 pm

VLD

Velo3D has been granted U.S. Patent #11999110 for 'Quality Assurance in Formation of Three-Dimensional Objects'. This patent could enhance Velo3D's technological capabilities and market position in the 3D printing industry.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 7:59 pm

GILD

The National Institutes of Health (NIH) has initiated two clinical trials to evaluate Gilead Sciences' long-acting HIV prevention injection, lenacapavir. These trials will focus on cisgender women and people who inject drugs. Gilead Sciences (NASDAQ:GILD) is sponsoring and funding the studies, which are part of the HIV Prevention Trials Network (HPTN). The trials will assess the safety, acceptability, and pharmacokinetics of lenacapavir, which is administered every six months. GILD shares are up 1.06% following the announcement.

Portfolio Pulse from Vandana Singh

June 04, 2024 | 7:57 pm